The annual proxy for this producer of medicine and vaccinations for pets and livestock had the following proposals:
- Proforma votes on directors, appointment of auditors, and “say-on-pay” advisory vote
Magni for and against proforma proposals:
- For directors – The board has a majority of independent directors and some have CEO/CFO experience with other companies. The compensation of directors is disclosed with a meaningful portion in equity where the equity has restrictions to align director incentives with long-term value creation.
- For auditors – There appear to be no controversies with the financial statements of the company.
- Against “say-on-pay” – The proxy materials made a commitment to shareholder engagement, however there was no information about engagement activities. The peer group was listed, though the criteria were very vague and subject to gerrymandering.
